

# Cancer research and French national cancer institute Going global ?



**RÉPUBLIQUE  
FRANÇAISE**

*Liberté  
Égalité  
Fraternité*



## **CANCER RESEARCH IN FRANCE: WHO IS DOING WHAT ?**

- **INSERM**
- **CNRS**
- **CEA**
- **CHU**
- **CENTRE DE LUTTE CONTRE LE CANCER**
- **INSTITUTS PASTEUR**
- **INRIA**
- **ENS**
- **EPHE**
- **BIG PHARMA, BIOTECH (R&D)**
- **ETC..**



RÉPUBLIQUE  
FRANÇAISE

*Liberté  
Égalité  
Fraternité*



## **INSERM:**

- **80 TEAMS, STAFF 1800 (15%)**

## **CNRS:**

- **190 TEAMS, STAFF 700**

# KEY FIGURES TEN-YEAR CANCER CONTROL STRATEGY



► Launched in February 2021

► 4 strategic challenges:

- IMPROVING PREVENTION
- LIMITING AFTER-EFFECTS AND IMPROVING PATIENTS' QUALITY OF LIFE
- ADDRESSING POOR PROGNOSIS CANCERS
- ENSURING THAT PROGRESS BENEFITS ALL

► 234 measures

- 2021-2025 roadmap proposed
- 78 actions launched in 2021

► €1.7Bn dedicated

## CANCER RESEARCH ACTIONS

### 2021

- 2 first programmes launched
  - Prevention (biology)
  - Reducing sequelae and improving quality of life
- €7.22M specifically devoted


### 2022

- 8 research programmes launched to date
- Total funding to date: €18.15M

# KEY FIGURES

## 2021 multi-year cancer research funding (INCa and ITMO Cancer-Aviesan): **€88.80M**

- **€54.28M** in biology and basic sciences, including **€4.28M** dedicated to specific paediatric cancer research programmes
- **€13.58M** in translational and integrated cancer research
- **€3.03M** in clinical research, such as promoting access to innovative drugs
- **€17.91M** in research in human and social sciences, epidemiology and public health applied to cancer




# KEY FIGURES

2007-2021 multi-year cancer research funding  
(INCa, DGOS and ITMO Cancer-Aviesan):

**€1.427 Bn**

- **€584M** in biology and basic sciences
- **€377M** in clinical research
- **€310M** in translational and integrated cancer research
- **€156M** in research in human and social sciences, epidemiology and public health
  - ➔ 50% oriented research
  - ➔ 50% investigator driven research



# Is national effort enough to address major questions in cancer ?

---

- **Rising costs**
- **> €1M for a paper in a high-impact journal**
- **Slow progress, only incremental gain in many areas**
- **Large cohort needed**
- **Specific expertise not always available**
- **Biology moving to Big Science**

**→ Better to invest in international programs ?**